Showing results (331-340 of 396) with videos related to

Sort By:
Pageof 40
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 9, 2026
How should primary pulmonary sarcoma be staged? Results of an International Multicenter AnalysisTheresa Stork, Dagmar Adamkova, Clemens Aigner, et al.
Frontiers in Oncology|August 8, 2020
Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research PurposesEnrico Melis, Enzo Gallo, Simona di Martino, et al.
Nature Communications|May 3, 2024
CD74 supports accumulation and function of regulatory T cells in tumorsElisa Bonnin, Maria Rodrigo Riestra, Federico Marziali, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
JTCVS Open|December 31, 2025
Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective studyStephane Collaud, Theresa Stork, Dagmar Adamkova, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Real-World Treatment Patterns and Survival in Patients with <i>ROS1</i>-Positive Advanced Non-Small Cell Lung Cancer in Canada and EuropeWinson Y Cheung, Adam Lee, Helena Bote de Cabo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Pageof 40